<DOC>
	<DOCNO>NCT02096601</DOCNO>
	<brief_summary>An open label phase I/IIa study evaluate safety tolerability 6 different doses/ infusion rate subcutaneous ( SC ) ND0612 solution PD patient ; determine continuous delivery levodopa carbidopa provide reduce variability plasma concentration ; test compare PK profile high low concentration CD ; ass preliminary efficacy .</brief_summary>
	<brief_title>A Pharmacokinetic Study ND0612 Delivered Continuous Subcutaneous Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Male female PD patient race age 30 80 year 2 . PD diagnosis consistent UK PD Society Brain Bank criterion . 3 . Stable dos anti PD drug least 30 day 4 . PD patient welldefined morning `` OFF '' good response LD 5 . MMSE score &gt; 26 6 . No clinically significant medical , psychiatric laboratory abnormality 1 . Atypical secondary Parkinsonism . 2 . Acute psychosis hallucination . 3 . Subjects treat neuroleptic 4 . History melanoma significant skin disorder . 5 . Prior neurosurgical procedure PD . 6 . Patients history drug abuse alcoholism 7 . Clinically significant ECG abnormality . 8 . Renal liver dysfunction 9 . Subjects participate another clinical study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Motor fluctuation</keyword>
	<keyword>levodopa pharmacokinetics</keyword>
	<keyword>levodopa carbidopa solution</keyword>
	<keyword>continuous subcutaneous delivery</keyword>
</DOC>